Development of Candidate Medical Countermeasures (MCMs) and Technologies Against Radiological/Nuclear or Chemical Threats (U01 Clinical Trial Not Allowed)

The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the NIH mission by supporting research on concepts and technologies to address civilian radiation or chemical threats. Research is administered by NIAID on behalf of NIH via the Radiation and Nuclear (RNCP), and the Chemical Countermeasures (CCRP) Research Programs. A shared congressional mandate to the NIH OD (119 Stat. 2850; Public Law 109-149-Dec. 30, 2005), supports research to develop new ideas and technologies to diagnose, mitigate, and treat acute and delayed effects of radiation or chemical exposures during and after a public health emergency.

RNCP: Supports development of radiation-focused models, biomarkers of damage, devices to assess and predict injury, and products to improve survival and reduce morbidity across multiple organ systems.

CCRP: Supports preclinical work on products to mitigate and treat injuries after exposure to government-designated Chemicals of Concern. Candidates with efficacy in a post-exposure, civilian mass casualty setting are sought.

Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.